NCT06439836 - Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions

Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma

Interventions

PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Emavusertib

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET

Trial Locations (5)

10029

RECRUITING

Mount Sinai Hospital, New York

33136

RECRUITING

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

92093

RECRUITING

UC San Diego Moores Cancer Center, La Jolla

92868

RECRUITING

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH